Article (Scientific journals)
A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.
Vergote, Ignace; Schilder, Russell J.; Pippitt, Charles H. Jr et al.
2014In Gynecologic Oncology, 135 (1), p. 25-33
Peer Reviewed verified by ORBi
 

Files


Full Text
1-s2.0-S0090825814010786-main.pdf
Publisher postprint (450.81 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Angiogenesis; Angiopoietins; Combination treatments; Dose-limiting toxicities; Targeted therapy; Tie2 receptor
Abstract :
[en] OBJECTIVE: To examine the tolerability and antitumor activity of trebananib plus pegylated liposomal doxorubicin (PLD) or topotecan in recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. METHODS: In this open-label phase 1b study, patients received trebananib 10mg/kg or 15mg/kg IV QW plus PLD 50mg/m(2) (cohorts A1 and A3, respectively) or topotecan 4mg/m(2) (cohorts B1 and B3, respectively). Endpoints were dose-limiting toxicity (DLT; primary); treatment-emergent adverse events (AEs), overall response rate, anti-trebananib antibodies, and pharmacokinetics (secondary). RESULTS: 103 patients were enrolled. One patient in A1 and B1 had DLTs. Across all cohorts, the most common AEs were nausea, fatigue, and peripheral edema. Across both trebananib plus PLD cohorts (A1/A3), grade 4 AEs were pulmonary embolism, disease progression, and anemia. Two patients had grade 5 intestinal perforation (n=1) and sudden death (n=1). Across both trebananib plus topotecan cohorts (B1/B3), grade 4 AEs were neutropenia, hypokalemia, decreased granulocyte count, chest pain, dyspnea, decreased neutrophil count, and pulmonary embolism. Two patients had grade 5 disease progression. One patient had grade 5 pleural effusion associated with progressive disease. Confirmed objective response rates were 36.0% (A1), 34.8% (A3), 16.7% (B1), and 0.0% (B3). Median progression-free survival duration (months) was 7.4 (A1), 7.1 (A3), 3.5 (B1), and 3.1 (B3), respectively. No drug-drug interactions were apparent. CONCLUSIONS: Trebananib 10mg/kg and 15mg/kg IV QW plus PLD or topotecan appear to have acceptable toxicity profiles in recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. Antitumor activity was evident across all cohorts.
Disciplines :
Surgery
Author, co-author :
Vergote, Ignace
Schilder, Russell J.
Pippitt, Charles H. Jr
Wong, Shirley
Gordon, Alan N.
Scudder, Sidney
Kridelka, Frédéric ;  Université de Liège - ULiège > Département des sciences cliniques > Gynécologie-Obstétrique
Dirix, Luc
Leach, Joseph W.
Ananda, Sumitra
Nanayakkara, Nuwan
Melara, Rebeca
Bass, Michael B.
Litten, Jason
Adewoye, Henry
Wenham, Robert M.
More authors (6 more) Less
Language :
English
Title :
A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.
Publication date :
2014
Journal title :
Gynecologic Oncology
ISSN :
0090-8258
eISSN :
1095-6859
Publisher :
Elsevier, Atlanta, United States - California
Volume :
135
Issue :
1
Pages :
25-33
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
Copyright (c) 2014 Elsevier Inc. All rights reserved.
Available on ORBi :
since 24 November 2014

Statistics


Number of views
140 (3 by ULiège)
Number of downloads
774 (0 by ULiège)

Scopus citations®
 
19
Scopus citations®
without self-citations
17
OpenCitations
 
20

Bibliography


Similar publications



Contact ORBi